ClinicalTrials.Veeva
Menu

Find clinical trials for Melanoma in Taipei City

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Cancer
Carcinoma
Non-Small-Cell Lung Carcinoma
Squamous Cell Carcinoma of Head and Neck
Renal Cell Carcinoma
Lung Cancer
Cutaneous Malignant Melanoma

Melanoma trials near Taipei City, TWN:

A Study to Evaluate Similarity of ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Resected Melanoma

(PK) similarity and efficacy, safety, and immunogenicity of ABP 206 compared with OPDIVO® (nivolumab) in subjects with resected advanced melanoma...

Active, not recruiting
Melanoma
Drug: EU-authorized Nivolumab
Drug: ABP 206

Phase 3

Amgen
Amgen

Taipei, Taiwan and 110 other locations

assess the efficacy, safety, and immunogenicity of ABP 206 compared with Nivolumab in Subjects with Treatment-Naïve Unresectable or Metastatic Melanoma...

Enrolling
Melanoma
Drug: ABP 206
Drug: Nivolumab

Phase 3

Amgen
Amgen

Taipei, Taiwan and 185 other locations

is safe and prevents cancer from returning in people with high-risk melanoma. Researchers want to know if intismeran autogene with pembroliz...

Active, not recruiting
Melanoma
Biological: Intismeran autogene
Biological: Pembrolizumab

Phase 3

Merck Sharp & Dohme (MSD)
Merck Sharp & Dohme (MSD)

Taipei, Taiwan and 165 other locations

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of KIN-2787 in adults with BRAF/NR...

Enrolling
Melanoma
Solid Tumor, Adult
Drug: KIN-2787 and binimetinib
Drug: KIN-2787

Phase 1

Pierre Fabre
Pierre Fabre

Taipei, Taiwan and 38 other locations

and DKY709 in combination with PDR001 in subjects with NSCLC or melanoma who have received prior anti-PD-1/PD-L1 therapy, or subjects with N...

Active, not recruiting
Melanoma
Nasopharyngeal Carcinoma
Drug: DKY709
Drug: PDR001

Phase 1

Novartis
Novartis

Taipei, Taiwan and 8 other locations

solid tumors. The study is enrolling cohorts of participants with melanoma \[cutaneous/acral\], squamous cell carcinomas of the head and nec...

Enrolling
Melanoma
Breast Cancer
Drug: HER3-DXd

Phase 2

Daiichi Sankyo
Daiichi Sankyo

Taipei, Taiwan and 76 other locations

The purpose of this study is to characterize the safety and tolerability of KFA115 and KFA115 in combination with pembrolizumab in patients with sele...

Enrolling
Cutaneous Melanoma
Anal Cancer
Drug: pembrolizumab
Drug: KFA115

Phase 1

Novartis
Novartis

Taipei, Taiwan and 18 other locations

with locally advanced or metastatic solid tumors, including non-small-cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), melanoma...

Enrolling
Melanoma
Clear Cell RCC
Drug: RO7502175
Drug: Pembrolizumab

Phase 1

Genentech
Genentech

Taipei, Taiwan and 41 other locations

This is an open-label, multicenter, global Phase 2 basket study of entrectinib (RXDX-101) for the treatment of patients with solid tumors that harbor...

Active, not recruiting
Melanoma
Breast Cancer
Drug: Entrectinib

Phase 2

Roche
Roche

Taipei, Taiwan and 129 other locations

TransCon IL-2 β/γ is an investigational drug being developed for treatment of locally advanced or metastatic solid tumors. This is a first-in-human,...

Enrolling
Post Anti-PD-1 Melanoma
Neoadjuvant Melanoma
Drug: TransCon TLR7/8 Agonist
Drug: Trastuzumab emtansine (T-DM1)

Phase 1, Phase 2

Ascendis Pharma
Ascendis Pharma

Taipei, Taiwan and 68 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems